Elmiron linked to vision loss, blindness

RPWB attorneys are investigating cases in which people suffered maculopathy or other serious vision problems from using Elmiron, a drug widely prescribed for the bladder condition interstitial cystisis.

Recent studies show that Elmiron is toxic to the retina, tissue at the back of the eye that picks up light and allows us to see. A 2019 study of patients at Kaiser Permanente in Northern California found that one-quarter of patients taking Elmiron suffered vision loss. Subsequent studies have confirmed that Elmiron can damage eyesight.

Elmiron users who suffer from maculopathy or other serious vision problems may be eligible for compensation from the drug’s manufacturer, Janssen Pharmaceuticals, which has not warned US patients that the drug carries the possibility of this very serious and irreversible side effect.

If you or a loved one has developed vision problems after using Elmiron, please give us a call 1-888-858-9085 or fill out to the form below to start your free, no obligation case review. RPWB lawyers are leaders in the field of pharmaceutical litigation, and have decades of experience leading large national lawsuits against the makers of dangerous drugs.

Studies show Elmiron Causes Retina Toxicity Leading to Blindness

Interstitial cystisis is a condition of the bladder that includes chronic pain in the bladder and pelvis area. It is estimated that about one million people, most of whom are women, suffer from the condition. As the primary FDA-approved treatment for IC, hundreds of thousands of people have been prescribed Elmiron for decades.

Researchers recently studied 91 patients who had taken an average of 5,000 pills each over the course of 15 years. The research team took detailed images of the back of the patients’ eyes. Twenty-two of the 91 patients showed clear signs of drug toxicity and others showed possible signs. The rate of toxicity rose with the amount of drug consumed, from 11 percent of those taking 500 to 1,000 grams to 42 percent of those taking 1,500 grams or more. A follow up study of 117 Elmiron users found similar results in January 2020.

In 2019, regulators in Canada began requiring a specific warning to Elmiron patients stating that the drug causes some people to develop maculopathy. So far, the manufacturer has not added such warnings to Elmiron sold in the United States.

Why Choose RPWB

RPWB represents people throughout the country who were injured as a result of pharmaceutical drugs, medical devices and other unsafe products. Our firm is well-known for its powerful role on behalf of consumers who rely on pharmaceutical companies for safe and effective treatments. We have been appointed lead counsel in seven large multi-district litigations and leadership positions in many more. Our attorneys are sensitive to the wishes of our clients yet tenacious and experienced enough to secure the compensation our clients need and deserve.

Start Your Elmiron Case Review

Give Us A Call

1-888-858-9085